The interplay between antidiabetic medications and cancer risk

Abstract

Diabetes mellitus (DM) refers to a group of metabolic disorders marked by chronic hyperglycemia. Its primary cause usually involves impaired insulin secretion or impaired insulin action. Its prevalence is escalating globally. Type II DM (T2DM) is becoming more common, and it is expected to afflict 7.7% (439 million) of persons aged 20 to 79 by 2030. Diabetes appears to be linked to an increased risk of a variety of cancers, ranging from a 20 to 30% greater risk of breast or colorectal cancer to a 97% increased chance of intrahepatic cholangiocarcinoma or endometrial cancer. Shared risk factors and potential biochemical pathways have prompted investigations into the effect of antidiabetic medications (ADMs) on cancer risk. We intend to investigate the link between diabetes drugs and cancer development.